

TEST REPORT NO 175587/25/GDY

Client NADARRA GmbH Harvestehuder Weg 48 20149 Hamburg		Sample (according to declaration of Client) Sample description: Erholung Nadarra, 120 capsules Batch: ERN/26022025 Production date: 26.02.2025 Expiry date: 26.02.2027
Sample reception date:	15.03.2025	Sample status: no objections
Start of analysis	26.03.2025	
End of analysis	27.03.2025	
Test report date	27.03.2025	
		Sample received from the Client

Test Method	Unit	Result	Criteria	Statement of conformity
* Vitamin B2 (ryboflawin) ^{1) 2) 3) 4)} PN-EN 14152:2014-07				
Vitamin B ₂ (ryboflawin)	mg/dose	1,59 ± 0,32	1,4 (+50%/-20%)	Pass

- 1) Capsule weight declared by the Client: 800 mg.
- 2) Dose declared by the Client: 2 capsules.
- 3) Guidance Document for competent authorities for the control of compliance with EU legislation on: Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004 and Council Directive 90/496/EEC of 24 September 1990 on nutrition labelling of foodstuffs and Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements with regard to the setting of tolerances for nutrient values declared on a label, December 2012. Table 2.
- 4) Client specification.

Authorized by:
ID: 127, Analysis Expert, Vitamin Analysis Laboratory

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

Laboratory address:
Chwaszczyska 180, 81-571 Gdynia


The results refer only to the samples received. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with IAC-G8:09/2019, unless otherwise reported. If the "result" column of the accredited method contains a record "¹⁾ or "²⁾", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the accredited method, whereas the given expanded measurement uncertainty relates only to the lower or upper limit of the measuring range of the accredited method respectively. In such a case, the Laboratory presents the opinion and interpretation in the "statement of conformity" column, which is based on the obtained test outcome. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
Test performed by external provider

THE END OF THE REPORT


Page 1 / 1

J.S. HAMILTON POLAND Sp. z o.o.
TESTING LABORATORY
Chwaszczyska 180, 81-571 Gdynia, Poland tel. +48 58 766 99 00



HAMILTON

LABORATORIES



AB 079

TEST REPORT NO 175588/25/GDY

Client NADARRA GmbH Harvestehuder Weg 48 20149 Hamburg		Sample (according to declaration of Client) Sample description: Erholung Nadarra, 120 capsules Batch: ERN/26022025 Production date: 26.02.2025 Expiry date: 26.02.2027
Sample reception date:	15.03.2025	Sample status: no objections
Start of analysis	26.03.2025	
End of analysis	27.03.2025	
Test report date	27.03.2025	
		Sample received from the Client

Test Method	Unit	Result	Criteria	Statement of conformity
* Vitamin B6 ^{1) 2) 3) 4)} PN-EN 14164:2014-08				
Vitamin B ₆ (pyridoxine hydrochloride)	mg/dose	1,38 ± 0,28	-	-
Vitamin B ₆ (pyridoxine)	mg/dose	1,14 ± 0,23	1,4 (+50%/-20%)	Pass

1) Dose declared by the Client: 2 capsules.

2) Capsule weight declared by the Client: 800 mg.

3) Guidance Document for competent authorities for the control of compliance with EU legislation on: Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004 and Council Directive 90/496/EEC of 24 September 1990 on nutrition labelling of foodstuffs and Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements with regard to the setting of tolerances for nutrient values declared on a label, December 2012. Table 2.

4) Client specification.

Authorized by:
ID: 758, Analysis Expert, Vitamin Analysis Laboratory

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

Laboratory address:
Chwaszczyska 180, 81-571 Gdynia

The results refer only to the samples received. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with IAC-G8:09/2019, unless otherwise reported. If the "result" column of the accredited method contains a record "¹⁾ or "²⁾", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the accredited method, whereas the given expanded measurement uncertainty relates only to the lower or upper limit of the measuring range of the accredited method respectively. In such a case, the Laboratory presents the opinion and interpretation in the "statement of conformity" column, which is based on the obtained test outcome. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
Test performed by external provider


THE END OF THE REPORT

Page 1 / 1

J.S. HAMILTON POLAND Sp. z o.o.
TESTING LABORATORY
Chwaszczyska 180, 81-571 Gdynia, Poland tel. +48 58 766 99 00



PO-14/F-01, issue 07 of 03-03-2025

Page 1 / 1



ANALYTICAL LABORATORIES

microbiology - physicochemistry - sensory



AB 1095

TEST REPORT No: B/0/03/2025/551/F/EN

Customer: Nadarra GmbH 20149 Hamburg, Harvestehuder Weg 48

Order No: B/0/03/2025/551

A - accredited methodology (accreditation no. AB 1095); reference – if the law so provides (the result can be used to assess compliance in the legally regulated area).

Material/product tested: Dietary supplements		Date*: 13 March 2025							
Sample collection address:									
Product name: Erholung Nadarra, 120 capsules									
Producer: Nadarra GmbH									
Date of production: 26.02.2025									
Lot number: ERN/26022025									
Sampling according to: -									
Samples transported by: Shipping		Received by: GBA POLSKA employee no.: 2729							
Sample no: 24486/03/25	Sample condition: correct	Analysis start date: 13-03-2025	Analysis end date: 25-03-2025						
Lab.	Analysis reference	Unit	Accred.	Test method	Requirement	Result	U	S	OI
M	Vitamin B12 content (as methylcobalamin)	µg/100g	A	PB-304/LF ed. 2 of 26.03.2025	no requirements	629	126	-	-

Data* - depending on the method of obtaining the sample by GBA POLSKA, it is the date of collection (when the sample is collected only by a GBA POLSKA employee) or receipt (when the sample is collected from the Customer by a GBA POLSKA employee, is delivered by a courier company or delivered personally by the Customer).

U - expanded measurement uncertainty at the level of confidence app. 95% and the coverage factor k=2, does not take into account the sampling uncertainty, except when indicated in the remark. Measurement uncertainty is provided when it is important for the reliability of test results or compliance with requirements/specifications and at the request of the Customer. The "test results" lower or higher than the measuring ranges of the methods are presented as "¹⁾ value of the lower limit of the measuring range" or "²⁾ value of the upper limit of the measuring range", respectively. These values provide information about the research results. If expanded uncertainties are given with these test results, they apply to the lower or upper limit of the measuring range of the method.

- Statement of Conformity with the requirements or specifications relating to the results for the parameters indicated as a given row, where CONFORMING means conformity and NON CONFORMING means non-conformity with specification. The decision rules agreed with the Customer and the risks associated with it, as well as the identification of which specifications, standards or parts thereof are met and which are not, are provided in the Remarks. In case of obtaining the "test results", the statement of conformity for those "test results" that are meet the requirement of PCA Communication No. 373 of August 24, 2021, it is issued out as part of the opinion and interpretation.

OI - opinion and interpretation of the Laboratory in relation to the qualitative results results obtained below the method range, where MEET means complying with the requirements and NOT MEET means not complying with the requirements.

The results refer only to the tested samples (sampled or received - in accordance with the information prepared in the Test Report).

The information is initially included in the Test Report was provided by the Customer. The laboratory is not responsible for the method of sampling and the representativeness of the sample provided for the measurement for testing.

The Test Report without the written approval of the Laboratory shall not be reproduced except in full.

The Laboratory does not store the samples after testing, unless otherwise agreed with the Customer.

Place of performance of the tests ("Lab.") : L - Łajki, ul. Kościelna 2A, 05-119 Legionowo, L - ul. Dowiadaczała 50A, 20-280 Lublin, M - ul. Fabryczna 7, 41-404 Mysłowice, P - ul. Zamieszona Tytusieckiego 34, 60-681 Poznań, P5 - in situ measurement.

NOTE: Original Test Report are issued in electronic form with the *.pdf extension, signed with a qualified electronic signature. Therefore, all prints, unless certified as true copies, are copies.

Remarks:

Information from the Client-expected content of Vitamin B12 in the form of methylcobalamin: 5 µg / capsule, 10 µg / daily dose. Daily dose 2 capsules. Capsule weight 800mg.

Vitamin B12-Me = 5.03 +/- 0.1 µg/caps (800mg)

Created on: 25-03-2025	Authorized result: GBA POLSKA employee no.: 2522	Authorized Test report: Documentation specialist for the food testing industry GBA POLSKA employee no.: 2942	Signed with a qualified electronic signature
------------------------	--	---	--

Report prepared in a single copy

Original of PDF: Customer, copy of PDF to: Laboratory archive

The end of the Test Report

B/0/03/2025/551/F/EN



HAMILTON

LABORATORIES



AB 079

TEST REPORT NO 175584/25/GDY

Client NADARRA GmbH Harvestehuder Weg 48 20149 Hamburg		Sample (according to declaration of Client) Sample description: Erholung Nadarra, 120 capsules Batch: ERN/26022025 Production date: 26.02.2025 Expiry date: 26.02.2027
Sample reception date:	15.03.2025	Sample status: no objections
Start of analysis	20.03.2025	
End of analysis	21.03.2025	
Test report date	21.03.2025	
		Sample received from the Client

Test Method	Unit	Result	Criteria	Statement of conformity
* Magnesium (Mg) ^{1) 2) 3) 4)} PB-361/CF ed. 8 of 29.12.2022				
Mg	mg/dose	121 ± 31	120 (-20%/+45%)	Pass

1) Capsule weight declared by the Client: 800 mg.

2) Dose declared by the Client: 2 capsule.

3) Packaging label.

4) Guidance Document for competent authorities for the control of compliance with EU legislation on: Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC and 2008/5/EC and Commission Regulation (EC) No 608/2004 and Council Directive 90/496/EEC of 24 September 1990 on nutrition labelling of foodstuffs and Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements with regard to the setting of tolerances for nutrient values declared on a label, December 2012. Table 2.

Authorized by:
ID: 371, Senior Analysis Specialist, Spectrometry Laboratory

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

Laboratory address:
Chwaszczyska 180, 81-571 Gdynia

The results refer only to the samples received. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with IAC-G8:09/2019, unless otherwise reported. If the "result" column of the accredited method contains a record "¹⁾ or "²⁾", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the accredited method, whereas the given expanded measurement uncertainty relates only to the lower or upper limit of the measuring range of the accredited method respectively. In such a case, the Laboratory presents the opinion and interpretation in the "statement of conformity" column, which is based on the obtained test outcome. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
Test performed by external provider

THE END OF THE REPORT

Page 1 / 1

J.S. HAMILTON POLAND Sp. z o.o.
TESTING LABORATORY
Chwaszczyska 180, 81-571 Gdynia, Poland tel. +48 58 766 99 00



HAMILTON

LABORATORIES



AB 079

TEST REPORT NO 175586/25/GDY

Client NADARRA GmbH Harvestehuder Weg 48 20149 Hamburg		Sample (according to declaration of Client) Sample description: Erholung Nadarra, 120 capsules Batch: ERN/26022025 Production date: 26.02.2025 Expiry date: 26.02.2027
Sample reception date:	15.03.2025	Sample status: no objections
Start of analysis	24.03.2025	
End of analysis	14.04.2025	
Test report date	14.04.2025	
		Sample received from the Client

Test Method	Unit	Result	Criteria	Statement of conformity
# Hydroxytryptophan (5-HTP) ¹⁾ SOP 3.1.76				
# Hydroxytryptophan (5-HTP)	mg/dose	45,43 ± 2,27	-	-

1) Dose declared by the Client: 1600 mg.

Test: Hydroxytryptophan (5-HTP) was performed in laboratory Certified Laboratories, Inc. Tustin United States of America

Authorized by:
ID: 1091, Laboratories Communication Specialist, Cooperation with Laboratories Section

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

The results refer only to the samples received. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with IAC-G8:09/2019, unless otherwise reported. If the "result" column of the accredited method contains a record "¹⁾ or "²⁾", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the accredited method, whereas the given expanded measurement uncertainty relates only to the lower or upper limit of the measuring range of the accredited method respectively. In such a case, the Laboratory presents the opinion and interpretation in the "statement of conformity" column, which is based on the obtained test outcome. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
Test performed by external provider

THE END OF THE REPORT

Page 1 / 1

J.S. HAMILTON POLAND Sp. z o.o.
TESTING LABORATORY
Chwaszczyska 180, 81-571 Gdynia, Poland tel. +48 58 766 99 00



HAMILTON

LABORATORIES



AB 079

TEST REPORT NO 175585/25/GDY

Client NADARRA GmbH Harvestehuder Weg 48 20149 Hamburg		Sample (according to declaration of Client) Sample description: Erholung Nadarra, 120 capsules Batch: ERN/26022025 Production date: 26.02.2025 Expiry date: 26.02.2027
Sample reception date:	15.03.2025	Sample status: no objections
Start of analysis	24.03.2025	
End of analysis	22.04.2025	
Test report date	22.04.2025	
		Sample received from the Client

Test Method	Unit	Result	Criteria	Statement of conformity
# Gamma aminobutyric acid (GABA) ¹⁾ Internal method				
# Gamma aminobutyric acid (GABA)	mg/dose	199,89 ± 9,99	-	-

1) Dose declared by the Client: 2 capsules.

Test: Gamma aminobutyric acid (GABA) was performed in laboratory Certified Laboratories, Inc. Tustin United States of America

Authorized by:
ID: 1091, Laboratories Communication Specialist, Cooperation with Laboratories Section

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

The results refer only to the samples received. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with IAC-G8:09/2019, unless otherwise reported. If the "result" column of the accredited method contains a record "¹⁾ or "²⁾", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the accredited method, whereas the given expanded measurement uncertainty relates only to the lower or upper limit of the measuring range of the accredited method respectively. In such a case, the Laboratory presents the opinion and interpretation in the "statement of conformity" column, which is based on the obtained test outcome. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
Test performed by external provider

THE END OF THE REPORT

Page 1 / 1

J.S. HAMILTON POLAND Sp. z o.o.
TESTING LABORATORY
Chwaszczyska 180, 81-571 Gdynia, Poland tel. +48 58 766 99 00